Another recent study reported that the combination of <6 mitoses per 3 mm2 and a residual tumor volume of <1 cm2 upon postsurgical imaging was indicative of longer time to treatment and overall survival in patients with IDH-mutant astrocytomas of CNS WHO grade 2 or 3 [45]. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).